Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation?

Title: Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation?
Authors: Engelender, Simone; Stefanis, Leonidas; Oddo, Salvatore; Bellucci, Arianna
Contributors: Engelender, Simone; Stefanis, Leonida; Oddo, Salvatore; Bellucci, Arianna
Publication Year: 2022
Collection: Università degli Studi di Messina: IRIS
Subject Terms: autophagy lysosomal pathway; neurodegenerative proteinopathies; pathological protein aggregates; therapeutic strategies; ubiquitin proteasomal system
Description: Neurodegenerative proteinopathies are defined as a class of neurodegenerative disorders, with either genetic or sporadic age-related onset, characterized by the pathological accumulation of aggregated protein deposits. These mainly include Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) as well as frontotemporal lobar degeneration (FTLD). The deposition of abnormal protein aggregates in the brain of patients affected by these disorders is thought to play a causative role in neuronal loss and disease progression. On that account, the idea of improving the clearance of pathological protein aggregates has taken hold as a potential therapeutic strategy. Among the possible approaches to pursue for reducing disease protein accumulation, there is the stimulation of the main protein degradation machineries of eukaryotic cells: the ubiquitin proteasomal system (UPS) and autophagy lysosomal pathway (ALP). Of note, several clinical trials testing the efficacy of either UPS- or ALP-active compounds are currently ongoing. Here, we discuss the main gaps and controversies emerging from experimental studies and clinical trials assessing the therapeutic efficacy of modulators of either the UPS or ALP in neurodegenerative proteinopathies, to gather whether they may constitute a real gateway from these disorders. © 2022 International Parkinson and Movement Disorder Society.
Document Type: article in journal/newspaper
File Description: STAMPA
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/35579450; info:eu-repo/semantics/altIdentifier/wos/WOS:000796567700001; volume:37; issue:7; firstpage:1346; lastpage:1359; numberofpages:14; journal:MOVEMENT DISORDERS; https://hdl.handle.net/11570/3235848
DOI: 10.1002/mds.29058
Availability: https://hdl.handle.net/11570/3235848; https://doi.org/10.1002/mds.29058; https://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mds.29058
Rights: info:eu-repo/semantics/restrictedAccess
Accession Number: edsbas.C48A03FC
Database: BASE